Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Truffle Capital Unveils the First Edition of the Truffle MedTech 10

businesswire.com
PLSE Ranked first in the Truffle MedTech 10 index with a market cap of $1,380M, highlighting its leadership in the cardiovascular interventional MedTech sector. The company is based in the USA. AVR Ranked second in the Truffle MedTech 10 index with a market cap of $641M, focusing on cardiovascular interventional MedTech. The company has dual US and Australian presence. MBOT Ranked eighth in the Truffle MedTech 10 index with a market cap of $183M, specializing in cardiovascular interventional MedTech. The company is based in the USA. ABVX Mentioned as a successful Truffle Capital investment that reached $10Bn market capitalization on NASDAQ in 2025 due to strong Phase III results in ulcerative colitis, indicating significant growth and investor confidence.

Truffle Capital Unveils the First Edition of the Truffle MedTech 10 PARIS--( BUSINESS WIRE)--Truffle Capital, a leading European venture capital firm whose mission is to support the creation and growth of companies capable of becoming global leaders, unveils the Truffle MedTech 10 index. This is the first ranking of the top ten publicly traded companies by market capitalization in the pre-commercial and early commercial interventional MedTech sector.

Using PitchBook ( https://pitchbook.com) data as of March 12 th, 2026, this list identifies companies developing medical technologies dedicated to interventional therapeutic procedures. The ranking focuses specifically on "pre-commercial" and “early commercial” listed companies with 2025 reported revenues below 10 million USD.

Ranking

Company

Stock market

Market Cap ($M)

HQ location

Medical field

1

Pulse Biosciences

NAS: PLSE

1,380

USA

Cardiovascular

2

Anteris Technologies

ASX/NAS: AVR

641

USA / Aus

Cardiovascular

3

Jenscare

HK: 9877

472

China

Cardiovascular

4

Imricor

ASX: IMR

440

USA

Cardiovascular

5

EBR Systems

ASX: EBR

235

USA

Cardiovascular

6

Carvolix

EPA: CVX

220

France

Cardiovascular

7

ONWARD Medical

EBR: ONWD

214

Netherlands

Neuromodulation

8

Microbot Medical

NAS: MBOT

183

USA

Cardiovascular

9

Medinice

WSE: ICE

91

Poland

Cardiovascular

10

Creo Medical

LON : CREO

78

UK

Gastroenterology/

Pneumology/

Urology

Dominance of the Cardiovascular Sector

This first edition highlights a major trend: the predominance of the cardiovascular sector, which accounts for 8 out of 10 spots in the ranking. This concentration is driven by several key factors:

i. Major Medical Need: Cardiovascular pathologies remain a global health priority

ii. High Technology Adoption: Cardiac specialists (especially interventional cardiologists) are the most eager clinicians to adopt new technological solutions for new indications

iii. Massive Investment Dynamics: This field attracts the largest financing flows and remains a primary driver for M&A activity in the sector

Notably, no companies from the orthopedics sector appear in this first ranking.

USA in the Lead, Europe and China also represented

While the United States confirms its historical leadership with five represented companies -accounting for 75% of total market capitalizations of the Truffle MedTech 10 index and led by Pulse Biosciences ($1,380M)—the Truffle MedTech 10 index highlights notable geographic diversity. Europe demonstrates its competitiveness and capacity for innovation with the presence of France (Carvolix), the Netherlands and Switzerland (ONWARD Medical, HQ in Netherlands, R&D center in Switzerland), Poland (Medinice) and UK (Creo Medical). Finally, Jenscare’s 3 rd place ranking, with a market capitalization of $472M, highlights the emergence of the Chinese sector.

Philippe Pouletty, M.D., Co-Founder and CEO of Truffle Capital, stated: "This inaugural Truffle MedTech 10 index highlights the vitality of interventional MedTech, particularly in the cardiovascular field which largely dominates this ranking. These 'pre-commercial' and ‘early commercial’ companies are future leaders whose products will transform clinicians’ and patients’ lives. Their growing market capitalization demonstrates investor confidence in their ability to transform standards of care, democratize complex procedures and improve patient life. While the United States confirms its leadership, the emergence of European players is promising."

***

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European Venture Capital firm specializing in disruptive technologies in the Life Sciences (Biotech, MedTech) and IT sectors (Fintech and Insurtech). Truffle Capital's mission is to support the creation and development of innovative companies capable of becoming the leaders of tomorrow.

Managed by Philippe Pouletty, M.D. and Bernard-Louis Roques, Co-founders and co-CEOs, Truffle Capital manages €500 million in assets. Truffle Capital raised over €1.2 billion since its creation and has supported more than 124 companies in the life sciences and digital technology sectors.

In 2025, Abivax, biotech founded and funded by Truffle, reached $10Bn market capitalization on NASDAQ following strong Phase III results in ulcerative colitis. Truffle Capital recently replicated this Business Builder model on the MedTech Carvolix, integrating autonomous AI-driven mini-robotics solutions for heart valve replacement and brain stroke treatment.

Website: https://www.truffle.com/

LinkedIn: https://www.linkedin.com/company/truffle-capital/